Form 4: Zimmer Biomet CAO Stellato Reports Equity Transactions

Zimmer Biomet Holdings, Inc.'s VP, Controller, and CAO, Paul A. Stellato, reported the vesting of restricted stock units, acquisition of common stock, and new RSU grants.

Summary

• Paul A. Stellato, VP, Controller, and CAO of Zimmer Biomet Holdings, Inc. (ZBH), reported equity transactions on February 20, 2026.
• Stellato acquired 701 shares of common stock upon the vesting of restricted stock units.
• Concurrently, 362 shares of common stock were disposed of at $98.62 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Stellato beneficially owns 4,109 shares of common stock directly.
• The reported beneficial ownership also includes 60 shares acquired under the Employee Stock Purchase Plan on December 31, 2025.
• Stellato was granted 2,842 new Restricted Stock Units (RSUs) on February 20, 2026, which will vest annually over three years, commencing February 20, 2027.
• Additionally, 4,651 new RSUs were granted on February 20, 2026, vesting in full on February 20, 2028.
• After these transactions, Stellato beneficially owns 701 vested RSUs, 2,842 newly granted RSUs, and 4,651 newly granted RSUs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting ongoing executive equity participation and alignment with shareholder interests through new RSU grants, which is a standard practice in executive compensation.

Positives

• Acquisition of 701 shares of common stock through RSU vesting, increasing direct ownership.
• Grant of 2,842 new Restricted Stock Units, demonstrating continued equity incentive.
• Grant of 4,651 new Restricted Stock Units, further aligning executive interests with shareholder value.
• Participation in the Employee Stock Purchase Plan, acquiring 60 shares.

Negatives

• Disposal of 362 shares of common stock to satisfy tax withholding obligations, reducing direct share count.

Future Outlook

Paul A. Stellato has future equity incentives tied to Zimmer Biomet's performance, with 2,842 Restricted Stock Units vesting annually over three years starting February 20, 2027, and 4,651 Restricted Stock Units vesting in full on February 20, 2028.

Industry Context

StockSavvy.ai notes that these transactions are routine for executive compensation, reflecting standard equity incentive plans common across the medical device and healthcare industry. The grants of new Restricted Stock Units are a typical mechanism to align executive interests with long-term shareholder value, similar to practices observed at peers like Stryker or Medtronic.

Comparison to Industry Standards

• These equity transactions are consistent with common executive compensation practices in the medical technology sector.
• Similar RSU grants and vesting schedules are observed at companies like Stryker (SYK) and Medtronic (MDT), where executives receive performance-based or time-based equity awards to incentivize long-term commitment and performance.
• The tax withholding on vesting is also a standard procedure across all industries for equity compensation.

Related Party Transactions

• Paul A. Stellato, an officer of Zimmer Biomet Holdings, Inc., engaged in transactions involving the company's common stock and restricted stock units as part of his compensation.

Stakeholder Impact

• Shareholders: The grant of new RSUs aligns executive incentives with long-term shareholder value. The disposal of shares for tax purposes is a minor, routine event.
• Employees: The filing highlights the company's use of equity compensation, which can be a positive for employee retention and motivation, particularly for executives.

Next Steps

• Annual vesting of 2,842 Restricted Stock Units commencing February 20, 2027.
• Full vesting of 4,651 Restricted Stock Units on February 20, 2028.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including RSU vesting and new grants, along with associated tax withholdings. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions reflect standard practices for aligning executive interests with long-term company performance, thus supporting a 'hold' recommendation for existing investors.

Keywords

Zimmer Biomet, ZBH, Paul A. Stellato, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, common stock, equity compensation, employee stock purchase plan, tax withholding, corporate officer, beneficial ownership